Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul S Phillips

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Annals of Internal Medicine|June 17, 2009
Balancing randomized trials with anecdotePaul S Phillips
Annals of Internal Medicine|October 20, 2004
Ezetimibe and statin-associated myopathyPaul S Phillips
Nature Clinical Practice. Cardiovascular Medicine|November 3, 2005
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?Paul S Phillips
Expert Review of Cardiovascular Therapy|August 1, 2008
Statin myopathy as a metabolic muscle diseasePaul S Phillips, Richard H Haas
Archives of Internal Medicine|June 15, 2006
Observations from a statin myopathy clinicPaul S Phillips, Richard H Haas
JAMA|February 2, 2006
Atypical antipsychotic drugs, dementia, and risk of deathHarminder Sikand, Joyce Jaojoco, Leslie Linares, et al.
Journal of Environmental Radioactivity|June 29, 2005
The effects of geology and the impact of seasonal correction factors on indoor radon levels: a case study approachGavin K Gillmore, Paul S Phillips, Antony R Denman
Cleveland Clinic Journal of Medicine|June 3, 2011
Statin myopathy: a common dilemma not reflected in clinical trialsGenaro Fernandez, Erica S Spatz, Charles Jablecki, et al.
Journal of Environmental Radioactivity|August 13, 2002
A critical comparison of the cost-effectiveness of domestic radon remediation programmes in three counties of EnglandThomas Coskeran, Antony R Denman, Paul S Phillips, et al.
Journal of Environmental Radioactivity|February 19, 2002
The cost-effectiveness of residential radon remediation programmes: assumptions about benefits stream profiles over timeChristine A Kennedy, Alastair M Gray, Antony R Denman, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Annals of Internal Medicine|June 17, 2009
Balancing randomized trials with anecdotePaul S Phillips
Annals of Internal Medicine|October 20, 2004
Ezetimibe and statin-associated myopathyPaul S Phillips
Nature Clinical Practice. Cardiovascular Medicine|November 3, 2005
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?Paul S Phillips
Expert Review of Cardiovascular Therapy|August 1, 2008
Statin myopathy as a metabolic muscle diseasePaul S Phillips, Richard H Haas
Archives of Internal Medicine|June 15, 2006
Observations from a statin myopathy clinicPaul S Phillips, Richard H Haas
JAMA|February 2, 2006
Atypical antipsychotic drugs, dementia, and risk of deathHarminder Sikand, Joyce Jaojoco, Leslie Linares, et al.
Journal of Environmental Radioactivity|June 29, 2005
The effects of geology and the impact of seasonal correction factors on indoor radon levels: a case study approachGavin K Gillmore, Paul S Phillips, Antony R Denman
Cleveland Clinic Journal of Medicine|June 3, 2011
Statin myopathy: a common dilemma not reflected in clinical trialsGenaro Fernandez, Erica S Spatz, Charles Jablecki, et al.
Journal of Environmental Radioactivity|August 13, 2002
A critical comparison of the cost-effectiveness of domestic radon remediation programmes in three counties of EnglandThomas Coskeran, Antony R Denman, Paul S Phillips, et al.
Journal of Environmental Radioactivity|February 19, 2002
The cost-effectiveness of residential radon remediation programmes: assumptions about benefits stream profiles over timeChristine A Kennedy, Alastair M Gray, Antony R Denman, et al.
Pageof 3